Cartesian Therapeutics公司已成功获得来自K2 Healthventures的高达1.5亿美元非稀释性融资。与此同时，该公司宣布，其关键的Aurora三期临床试验的顶线数据预计将在2027年第一季度公布。这一系列进展为公司的研发管线提供了重要的资金支持，并标志着其核心疗法在重症肌无力治疗领域的开发进入了关键的数据读出阶段。
Cartesian Therapeutics公司已成功获得来自K2 Healthventures的高达1.5亿美元非稀释性融资。与此同时，该公司宣布，其关键的Aurora三期临床试验的顶线数据预计将在2027年第一季度公布。这一系列进展为公司的研发管线提供了重要的资金支持，并标志着其核心疗法在重症肌无力治疗领域的开发进入了关键的数据读出阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.